GcCell and LaFleur Join Forces for AI Development to Predict Prognosis of Immune Cell Therapy

Setting the Optimal Treatment Window for Each Patient

GcCell announced on the 23rd that it has signed a memorandum of understanding (MOU) with LaFleur to collaborate on the development of artificial intelligence (AI) for predicting suitability and prognosis of the immune cell therapy product, ImmunCell-LC Injection.

Yeom Changhwan, CEO of La Ple (left), and Kim Jaewang, CEO of GC Cell, are taking a commemorative photo at the business agreement signing ceremony for the "Development of Prognostic Prediction AI for Immune Cell Therapy" on the 22nd. GC Cell

The AI program currently being developed by LaFleur will predict the response rate of individual patients to immune cell therapy, thereby selecting those patients who are most likely to achieve optimal therapeutic outcomes. By identifying the point at which patient benefit is maximized, it will proactively assess the risk of recurrence and be used to formulate customized anti-cancer treatment strategies.

Through this agreement, GcCell will provide its accumulated research expertise and data to improve the predictive accuracy of the model, while LaFleur will leverage this to pursue personalized management and optimized treatment solutions for each patient.

Kim Jaewang, CEO of GcCell, said, "We will collaborate to provide the best therapeutic benefits to as many patients as possible."

This content was produced with the assistance of AI translation services.